Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite

Maestrelli, Piero; Zanolla, Luisa; Pozzan, M; Fabbri, Leonardo M.

doi:10.1016/j.jaci.2003.12.586

Cited by 80 publications

(73 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical efficacy (reduction of symptoms and/or need for medications) has been confirmed with grass (1102,1104,(1650)(1651)(1652)(1653)(1654)(1655), birch (1650,1651,(1656)(1657)(1658)(1659), ragweed (1660), Russian thistle (1661), Parietaria pollen (1662,1663), mites (1664)(1665)(1666)(1667)(1668)(1669) and cat (1670). It should be noted that three of the studies (1104,1660,1670) clearly demonstrated that the clinical effect is dose dependent.…”

Section: Aria: 2008 Updatementioning

confidence: 90%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,861

1,761

View full text Add to dashboard Cite

Section: Aria: 2008 Updatementioning

confidence: 90%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,861

1,761

View full text Add to dashboard Cite

“…This selection method using the drug prescriptions population database identified a cohort of patients with asthma with a high percentage (81%) of moderate-to-severe disease, higher than the 31% estimated in the overall population of asthmatics in Italy [28].…”

Section: Methodsmentioning

confidence: 99%

Carbon monoxide pollution is associated with decreased lung function in asthmatic adults

Canova¹,

Torresan²,

Simonato³

et al. 2009

Eur Respir J

View full text Add to dashboard Cite

The aim of the present study was to test the effects of exposure to air pollutants on lung function.A panel of 19 adult asthmatics living in Padua (Italy) was followed for five 30-day periods during 2 yrs consecutively (1,492 morning and 1,434 evening measures analysed). Peak expiratory flow (PEF) and forced expiratory volume in 1 s (FEV1) were measured using a pocket electronic meter. Daily levels of air pollutants and meteorological variables were collected at outdoor city monitoring sites.Significant inverse associations were observed between morning and evening PEF and carbon monoxide level (p50.01-0.03), without clear differences between lags (0-3 days). An increment of 1 mg?m -3 CO was associated with a PEF variation ranging -2.6--2.8%. All effect estimates on PEF for CO remained significant and even increased after controlling for particles with a 50% cut-off aerodynamic diameter of 10 mm (PM10), nitrogen dioxide and sulphur dioxide in single and multipollutant models. A similar trend was observed for FEV1, but the associations were nonsignificant. A nonsignificant inverse relationship between evening PEF and SO 2 was also detected. PEF and FEV1 were not related to PM10 and NO 2 concentrations. The present results indicate that, in this panel of adult asthmatics, the worsening of lung function is associated with exposure to gaseous pollutants and occurs at levels of CO and SO 2 lower than current European standards.

show abstract

“…The problem is that there are very few studies addressing whether and in what circumstances immunotherapy adds to conventional anti-asthma therapy in terms of reduced drug consumption, improved lung function or indeed any other outcome measure. In one such study [17], HDM SCIT administered for 3 years to adult atopic asthmatics sensitized to mite slightly but significantly reduced 'as required' bronchodilator usage and increased peak flow as compared with placebo, although cumulative inhaled corticosteroid dosages, symptoms, lung volumes and bronchial responsiveness to methacholine were unchanged. A more recent study [18] has suggested that HDM SCIT, when added to conventional asthma therapy may be corticosteroid sparing in children.…”

Section: Subcutaneous Immunotherapymentioning

confidence: 99%

Immunotherapy for allergic rhinitis

Walker¹,

Durham

Till

et al. 2011

Clin Experimental Allergy

147

125

View full text Add to dashboard Cite

SummaryAllergic rhinitis (AR) affects more than 20% of the population in the United Kingdom and western Europe and represents a major cause of morbidity that includes interference with usual daily activities and impairment of sleep quality. This guidance prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) is for the management of AR in patients that have failed to achieve adequate relief of symptoms despite treatment with intranasal corticosteroids and/or antihistamines. The guideline is based on evidence and is for use by both adult physicians and paediatricians practising allergy. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are indications and contraindications for immunotherapy, criteria for patient selection, the evidence for short-and long-term efficacy of subcutaneous and sublingual immunotherapy, and discussion on safety and the different modes of immunotherapy including, pre-seasonal and co-seasonal treatments. There are sections on children, allergen standardization, vaccines used in the United Kingdom, oral allergy syndrome, cost effectiveness of immunotherapy and practical considerations of undertaking immunotherapy including recommendations on who should undertake immunotherapy and dosing schedules. Finally, there is discussion on potential biomarkers of response to immunotherapy, the use of component-resolved diagnostics, novel approaches, alternative routes and potential areas for future research.Keywords aeroallergens, allergen, allergic rhinitis, allergen standardization, allergy to animals, allergy to house dust mites, asthma, BSACI, cat allergy, component-resolved diagnostics, cost effectiveness, dosing schedules, grass pollen, guideline, immunotherapy, oral allergy syndrome, perennial rhinitis, pollinosis, ragweed allergy, SAR, seasonal pollen induced rhinitis, subcutaneous immunotherapy, sublingual immunotherapy, tree pollen Submitted 19 February 2011; revised 6 May 2011; accepted 9 May 2011. Executive summaryUntreated rhinitis represents a major cause of morbidity that includes interference with usual daily activities and impaired sleep quality. Immunotherapy, both subcutaneous and sublingual, is an effective treatment for adults and children with severe allergic rhinitis (AR) that does not respond to conventional pharmacotherapy and allergen avoidance measures. The efficacy of immunotherapy depends on correct patient selection, the type of allergen and the product chosen for treatment. Each vaccine requires individual assessment before recommendation for routine use.

show abstract

Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite

Cited by 80 publications

References 30 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Carbon monoxide pollution is associated with decreased lung function in asthmatic adults

Immunotherapy for allergic rhinitis

Contact Info

Product

Resources

About